Telix Pharmaceuticals Limited (ASX:TLX)
15.31
+0.21 (1.39%)
Jul 21, 2026, 4:10 PM AEST
Telix Pharmaceuticals Employees
As of December 31, 2025, Telix Pharmaceuticals had 1,184 total employees, including 1,120 full-time and 64 part-time employees. The number of employees increased by 950 or 405.98% compared to the previous year.
Employees
1,184
Change
950
Growth
405.98%
Revenue / Employee
1.05M AUD
Profits / Employee
-9.27K AUD
Market Cap
5.20B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,184 | - | - | 1,120 | 64 |
| Mar 31, 2024 | 431 | 197 | 84.19% | 415 | 16 |
| Dec 31, 2022 | 234 | 76 | 48.10% | 234 | 0 |
| Dec 31, 2021 | 158 | - | - | 158 | 0 |
| Dec 31, 2017 | 9 | - | - | 9 | 0 |
Telix Pharmaceuticals News
- 2 hours ago - TLX591-Tx ProstACT SELECT Study Published in Cancers Journal - GlobeNewsWire
- 15 hours ago - Telix Pharma Q2 Revenue Rises 21%; Doses First Patient In Phase 3 LUTEON Trial; Shares Jump - Nasdaq
- 16 hours ago - Telix Pharmaceuticals (TLX) Reports Strong Q2 Revenue Growth and Upbeat FY 2026 Outlook - GuruFocus
- 17 hours ago - Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business - Nasdaq
- 1 day ago - Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewsWire
- 1 day ago - Telix Pharmaceuticals Earnings release: Q2 2026 - Filings
- 1 day ago - Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer - GlobeNewsWire
- 5 days ago - Telix Opens Australian GMP Facility; Doses First Patient In Phase 2 Prostate Cancer Trial - Nasdaq